Pharma and healthcare is one of the most heavily regulated industries, in which legal, regulatory and ethical issues intersect with day-to-day operations.
We understand its specifics – from authorisation proceedings and relations with health insurance companies to the protection of innovation and the resolution of disputes with patients.
We have experience with transactions in this segment, including acquisitions of pharmacy chains and healthcare provider networks, outpatient practices and polyclinics.
In pharma and healthcare, we provide services to
- pharmaceutical companies
- distributors
- pharmacists and pharmacy chains
- healthcare providers
- strategic and financial investors
- research institutions
Our services include:
For pharmaceutical companies:
- Marketing authorisation of medicinal products, registration of medical devices and foods for special medical purposes, categorisation and reimbursement from health insurance
- Authorisation proceedings and licences, communication with the State Institute for Drug Control (ŠÚKL), the Ministry of Health of the Slovak Republic, self-governing regions and the European Medicines Agency (EMA)
- Advertising of medicinal products and medical devices, promotional and educational activities
- Clinical trials and contractual documentation with investigators and trial sites
- Patents and supplementary protection certificates (SPCs), trademarks and packaging design
- Licence agreements, technology transfer and research and development collaboration
- Sale and acquisition of medicinal product portfolios and other product portfolios (asset deals)
- Transfers of marketing authorisations, changes of marketing authorisation holder and related proceedings before ŠÚKL and EMA
- Transaction documentation for portfolio transfers – purchase agreement, transfer of the marketing authorisation and pharmacovigilance documentation, know-how and manufacturing documentation
- Portfolio due diligence – status of marketing authorisations, pricing and reimbursement decisions, licensing and distribution commitments
- Post-transfer transition period – manufacturing and supply agreements (CMO/CDMO), temporary sales under the original marketing authorisation and sell-off of remaining stock
- Allocation of responsibility for pharmacovigilance, complaints and batch recalls
- Transfer of trademarks, domain names and marketing materials relating to the transferred portfolio
- Disputes concerning intellectual property, generics and unfair competition
- Compliance programmes, anti-corruption rules and rules for cooperation with healthcare professionals
For healthcare providers and pharmacies:
- Operating permits and communication with supervisory authorities
- M&A advice, negotiating terms in acquisition transactions
- Advice on financing operations and expansion
- Contracts and relations with health insurance companies
- Medical records, processing of health data and protection of patients' personal data
- Employment law advice and employment of healthcare professionals
- Representation in disputes with patients and in claims arising from improperly provided healthcare
- Compensation for damage to health and non-pecuniary harm
- Disputes with health insurance companies and representation before administrative and supervisory authorities
For distributors:
- Distribution, supply and logistics agreements
- Wholesale distribution authorisations, good distribution practice and traceability of medicinal products
- Re-export of medicines and the emergency supply system
- Supplier–customer relationships, terms and conditions and bonus schemes
- Competition issues in distribution and supply relationships
For investors:
- M&A advice on the purchase and sale of healthcare facilities, outpatient practices, polyclinics and pharmacies
- Acquisitions and sales of pharmacy chains and healthcare provider networks
- Acquisition and divestment of medicinal product portfolios and other product portfolios (asset deals)
- Due diligence focused on permits, contracts with health insurance companies and staffing
- Due diligence focused on intellectual property rights
- Investor entry, joint ventures
- Financing of acquisitions and projects in healthcare
For research institutions:
- Research collaboration agreements and consortium agreements with academic and industry partners
- Clinical trials – agreements with sponsors, investigators and healthcare providers, informed consent and insurance
- Material transfer agreements for biological and other material (MTAs) and contract research services agreements (CRO)
- Structuring intellectual property rights in research results
- Patent protection and intellectual property protection strategy
- Licensing and commercialisation of research results, technology transfer
- Setting up spin-off companies, investor entry and structuring relations between the founders and the institution
- Employee inventions, remuneration of inventors and internal policies
- Protection of know-how, trade secrets and confidentiality (NDAs)
- Processing of personal data and health data in research, biobanks
- Ethical and regulatory requirements
- Grant and subsidy funding – contractual terms, state aid and project sustainability
